Skip to content

Examining the Efficacy of tDCS in the Attenuation of Epileptic Paroxysmal Discharges and Clinical Seizures

Examining the Efficacy of tDCS in the Attenuation of Epileptic Paroxysmal Discharges and Clinical Seizures

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02960347
Enrollment
1
Registered
2016-11-09
Start date
2016-02-29
Completion date
2016-06-30
Last updated
2022-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ohtahara Syndrome

Brief summary

The current study examined the feasibility of High-Definition tDCS (HD-tDCS) in reducing epileptiform activity in a 30-month-old child suffering from early onset epileptic encephalopathy. HD-tDCS was administered over 10 intervention days spanning two weeks including pre- and post-intervention video-electroencephalography (EEG) monitoring.

Interventions

DEVICEHigh-definition (HD) transcranial direct current stimulator, HD-tDCS with 4x1 HD adaptor

Non-invasive focal neuromodulation

Sponsors

The City College of New York
CollaboratorOTHER
Herzog Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
10 Months to 36 Months
Healthy volunteers
No

Inclusion criteria

1. Initial diagnosis of Ohtahara syndrome/West syndrome/ Lennox-Gastaut syndrome by a pediatric neurologist using video-EEG 2. Ongoing synchronous Hypsarrhythmia 3. Modified Hypsarrhythmia with a consistent focus of paroxysmal discharges 4. Signed informed consent of parents/immediate legal guardian 5. Age 10 to 36 months 6. Infant should be in a steady state indicated by a baseline test of electrolytes and biochemistry blood test, heart rate, temperature, respiratory rate, and saturation.

Exclusion criteria

1. Metal in the cranium, skull defects, or skin lesions on scalp (cuts, abrasions, rash) at proposed electrode sites. 2. History of adverse reaction to neurostimulation 3. Significant ECG abnormality

Design outcomes

Primary

MeasureTime frame
change in seizure frequency from baselineday 1, day 3, day 5, day 6, day 8, day 10, day 13, day 20, day 27, day 33, day 40, day 50

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026